Biocon's Oncology Portfolio Expands: FDA Approves Pebrilzo™ Biosimilar for Breast Cancer
Biocon Limited received U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta® for HER2-positive breast cancer. This is Biocon's fifth oncology biosimilar approved in the U.S. The company has secured a licensed launch in the U.S. for Q3 2028 through an agreement with Genentech.
FDA approval of a new drug, especially in the oncology space, has a substantial impact on the company's market position, revenue potential, and patient access to treatments.
The U.S. FDA approval of a new biosimilar product is a significant positive development for the company, expanding its product portfolio and market access in oncology.
Biocon Limited announced that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta® (pertuzumab). This monoclonal antibody is used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells and further strengthens Biocon’s oncology portfolio.
Shreehas Tambe, CEO & Managing Director of Biocon Limited, stated that the FDA approval of PEBRILZO, their biosimilar pertuzumab, is a significant milestone in expanding access to high-quality biosimilars for patients with HER2-positive breast cancer. This marks Biocon’s fifth oncology biosimilar to receive U.S. FDA approval, advancing their commitment to providing affordable biologic medicines.
In September, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended marketing authorization for Biocon’s Pertuzumab biosimilar in Europe. Biocon has also entered into a global settlement and license agreement with Genentech, securing the earliest licensed launch date for PEBRILZO in the United States in Q3 of calendar year 2028.
PEBRILZO will join Biocon’s existing oncology portfolio, which includes Ogivri® (trastuzumab-dkst), Jobevne® (bevacizumab-nwgd), Fulphila® (pegfilgrastim-jmdb), and Aukelso® (denosumab-kyqq). The company’s pipeline also includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab, and pembrolizumab.
The press release also details the indications for PEBRILZO, including metastatic breast cancer and early breast cancer, along with warnings and precautions related to left ventricular dysfunction, embryo-fetal toxicity, infusion-related reactions, and hypersensitivity reactions. Common adverse reactions are also listed for different treatment regimens.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.